177Lu-PSMA-DKFZ-617 (Lu-PSMA), which is a DOTA derivative of the Glu-urea-Lys motif, was developed for the treatment of patients with metastatic PC [5, 6]. This evidence concerns the gene FOLH1 and pachyonychia congenita.